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ABSTRACT 
 
The Susceptibility Patterns of Eight Antimicrobial Agents for Potential 
 
Treatment of Rhodococcus equi  Pneumonia in Foals.   (December 2003) 
 
Steven Antonn Daniels, B.S., Texas A&M University
  
Chair of Advisory Committee:  Dr. Russell B. Simpson 
 
 
Rhodococcus equi is a common cause of severe pneumonia in foals, and is an 
opportunistic pathogen in immunocompromised humans.  In combination, erythromycin 
and rifampin are the most commonly used antimicrobials in treating R. equi in foals.  To 
provide reliable treatment, it is imperative to determine the mean inhibitory 
concentrations (MICs) of other antimicrobial agents in the event that certain strains of R. 
equi develop resistance to the current treatment.  Several strains of R. equi have 
developed resistance to various antibiotics.  In this study, R. equi strain 288 was 
completely resistant to rifampin with a MIC > 256ug/ml.  The MICs of ethambutol, 
clarithromycin, azithromycin, isoniazide, ethionamide, rifampin, erythromycin, and 
linezolid of ninety-five R. equi isolates were also determined in this study. These isolates 
were obtained from the lungs and transtracheal washes of foals. In addition to these 
strains, three National Committee for Laboratory Clinical Standards (NCCLS) quality 
control strains were also tested: R. equi ATCC 6939, R. equi ATCC 33701, and S. 
pneumoniae 49619.  Each drug was tested in triplicate and the MIC 50’s and MIC 90’s 
were determined for each drug.  Ethambutol, isoniazide, and ethionamide were 
completely ineffective against R. equi. with MICs > 250ug/ml. Rhodococcus equi strains 
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were more susceptible to clarithromycin (MIC 90 = 0.23 ug/ml) than to  azithromycin 
(MIC 90 = 2.33 ug/ml), rifampicin (MIC 90 = 0.67ug/ml), erythromycin (MIC 90 = 
1.2ug/ml), and linezolid (MIC 90 = 4ug/ml).   
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  Rhodococcus equi (formerly Corynebacterium equi) is a common cause of severe 
bacterial pneumonia in foals (Barton and Hughes, 1980), and is of emerging importance 
in humans.  Controlling R. equi pneumonia of foals can be demoralizing, difficult, 
expensive, and frustrating (Hooper-McGrevy and Prescott, 2001b).  The organism was 
first reported to cause disease in horses in the 1920s and humans in the 1960s (Beaman 
et al., 1995).  Since then, researchers have identified R. equi in a variety of animals, 
including cattle, goats, swine, buffalo, sheep, (Weinstock and Brown, 2002) and a host 
of other mammals. R. equi is a facultative intracellular (Nordmann and Ronco, 1992) 
soil-borne organism with the ability to survive in lung macrophages and other tissues in 
the presence or absence of oxygen (Carter et al.,1995).  Although the lung is the primary 
organ affected by R. equi, this pathogen has been cultured from other tissues such as the 
prostate, spleen, and kidney (Weinstock and Brown, 2002).  In addition, intestinal 
manifestations, non-septic polysynovitis, septic arthritis and osteomyelitis may occur in 
infected foals (Giguere and Prescott, 1997).  In humans, this disease is commonly seen 
in immunocompromised individuals that are infected with the human immunodeficiency 
virus, HIV (Bowersock et al., 2000).   
______________ 
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  Young foals, during the first few weeks of life, are particularly vulnerable to R. 
equi most likely because of ineffective or inefficient immune systems.  The disease in 
foals is most commonly diagnosed when signs are manifested between the ages of 4 and 
12 weeks (Sweeney et al., 1987), but infections are thought to occur much earlier.  
Following infection, lesions usually develop insidiously for several weeks or months, at 
which time foals exhibit clinical signs of disease.  Foals are refractory to infection by 3 
months of age, and adult horses are rarely infected.  Rhodococcus equi is a soil 
saprophyte that can propagate and survive long periods in the manure of horses (Carter 
et al., 1995) and other herbivores during the warm months.  The fact that the organism is 
shed in the feces of dams and the dry environment on the farms is thought to play a very 
important role in the initial colonization of R. equi in foals (Takai et al., 1987).  
  Virulence of R. equi in foals is strongly associated with the presence of an 85-to 
90-kilobase (kb) plasmid and expression of a 15- to 17-kilodalton (kd) virulence 
associated protein antigen (VapA) encoded by that plasmid (Takai et al., 1991a; Takai et 
al., 1991b).  Infection in foals causes high mortality rates because the disease is difficult 
to recognize during its early stages, when therapy is most effective, and the organism is 
resistant to many antimicrobial drugs.  In the United States, it has been estimated that 
approximately 3% of foal deaths are caused by R. equi  (Madigan et al., 1991).   
  Treating infected foals with inappropriate antimicrobial drugs may also contribute 
to high mortality rates.  Designing antimicrobial therapeutic schemes for use in infected 
foals requires information on the susceptibility of the organism to antimicrobial agents 
(Prescott, 1981).  Minimum Inhibitory Concentrations (MIC) of several antimicrobial 
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agents have been determined in an effort to develop aggressive antimicrobial drug 
therapy combinations (Prescott and Sweeney, 1985).  The MIC values are divided into 
fifty and ninety percentiles.  An MIC 50 indicates that 50% of the isolates tested are 
inhibited at a given value and an MIC 90 indicates that 90% of the isolates tested are 
inhibited at a given value.  These values indicate the drug concentrations required to kill 
or inhibit the growth of an organism and are used to monitor the levels of resistance in a 
population tested.  Antimicrobial MIC data, in conjunction with pharmacokinetic data 
for the target species, are crucial for the development of therapeutic regimens.  
Successful treatment of R. equi infections requires antibiotics that penetrate and 
concentrate in infected cells.  Two such antibiotics, erythromycin and rifampin are 
commonly used to treat R. equi infections in the United States (Hillidge, 1987). Resistant 
isolates of R. equi to erythromycin and rifampin have been identified (Takai et al., 
1997).  Several, orally active, synthetic antimicrobial agents (Bowersock et al., 2000), 
which are similar in activity to erythromycin and rifampin, have been developed.  The 
properties of azithromycin and clarithromycin suggest that they may be an alternative to 
erythromycin for the therapy of R. equi pneumonia in foals (Davis et al., 2002).  There 
are currently no effective vaccines available for the prevention of R. equi infections.   
Studies have shown that the administration of R. equi hyperimmune plasma has a 
protective effect if given before infection (Martens et al., 1989; Madigan et al., 1991; 
Higuchi et al., 1999).  However, this strategy is expensive, labor intensive, and not 
universally effective.    
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CHAPTER II 
BACKGROUND AND SIGNIFICANCE 
2.1  Pathogenesis of Rhodococcus equi 
 Rhodoccocus equi is a facultative intracellular (Nordmann and Ronco, 1992) 
soil-borne bacterium that can live and proliferate in foal macrophages.  This organism 
causes pyogranulomatous lung lesions and death if not detected and treated early in the 
course of disease.  The pathogenesis of R. equi pneumonia is not fully understood, but 
disease appears to develop after inhalation of an adequate number of virulent R. equi 
that, although effectively phagocytized by alveolar macrophages, are not killed.  Failure 
of foal macrophages to kill R. equi is thought to be caused by some undefined 
immaturity of the immune system (Prescott and Sweeney, 1985).  Therefore, R. equi 
targets alveolar macrophages, which provide a stable environment wherein the organism 
can survive and proliferate.  In nearly all infected foals, the virulence of R. equi is 
strongly associated with a surface antigen, VapA, that is encoded by a gene on an 85-
90kbp plasmid (Takai et al., 1991a; Takai et al., 1991b).  Foals infected with VapA-
positive isolates develop severe bronchopneumonia, whereas plasmid-cured derivatives 
are innocuous (Weinstock and Brown, 2002).  Notable advancements in the 
understanding of R. equi pneumonia in foals have been made during the years, but 
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2.2  Previous Studies on Rhodoccocus equi 
 Rhodoccocus equi has been recognized since the early 1900s.  Due to high 
mortality rates of foals on ranches and farms, the importance of aggressive drug therapy 
and preventive methods has increased.  Although an effective vaccine is not yet 
available, passive immunization of foals with hyperimmune plasma (HIP) has become a 
standard and beneficial practice on many farms with endemic R. equi problems (Hooper-
McGrevy et al., 2001a).  This method has been thought to reduce the number of foals 
becoming infected with R. equi at an early age.  
  The combined therapy with erythromycin and rifampin has dramatically improved 
the survival rate of foals infected with R. equi (Jacks et al., 2003).  Antimicrobial 
susceptibility patterns are an important component of the decision-making process when 
determining appropriate therapeutic regimens. Prescott conducted a study on the 
susceptibility of isolates of R. equi to antimicrobial drugs (Prescott, 1981).  He 
demonstrated the MIC of both equine and porcine origin strains belonging to two 
different capsular serotypes, and concluded that there were no significant differences in 
antibiotic susceptibility patterns between source or serotype of the R. equi isolates tested.  
His study showed that R. equi was susceptible to erythromycin and gentamicin based 
upon the MIC values.  
 Prescott and colleagues continued their study on susceptibility of different 
isolates of R. equi (Prescott and Sweeney, 1985).  The objective was to develop a 
therapeutic regimen that would target the site of infection and continue to penetrate 
infected cells for an extended period of time.  Foals treated early in the course of disease 
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respond better than do those with chronic infections (Prescott and Sweeney, 1985).  
Treatment, however, must be aggressive and prolonged because of the extensive lung 
damage, presence of large abscesses, intracellular location of the organism, and the slow 
response to treatment (Prescott and Sweeney, 1985).  Prescott and Sweeney 
hypothesized that despite predictability of antibiotic susceptibility, mutants resistant to 
antimicrobial agents may emerge if drugs are used alone rather than in combination.   
Sweeney et al (1987) reported on the response of forty-eight pneumonic foals to 
antimicrobial therapy. They concluded that erythromycin and rifampin constituted the 
most successful antimicrobial drug combination.  Eighty-eight percent of the infected 
foals in Sweeney’s study recovered with this treatment (Sweeney et al., 1987).  In Japan, 
gentamicin and other compounds such as imipenem are used more generally, as the side 
effects of erythromycin can be problematic (Takai et al., 1995).  Erythromycin is 
tolerated by most foals, but severe diarrhea, hyperthermia and depression may develop 
leading to dehydration and electrolyte loss that necessitate intensive fluid therapy and 
cessation of oral erythromycin (Giguere and Prescott, 1997).  Sweeney et al (1987) also 
hypothesized that antimicrobial drugs should probably be directed not only against R. 
equi, but also against other organisms such as Streptococcus zooepidemicus that might 
be present. 
 Hillidge expanded the work of Sweeney by utilizing an erythromycin-rifampin 
drug combination in the treatment of foals with R. equi pneumonia (Hillidge, 1987).  
They realized that the selection of lipid-soluble antibiotics was important to successful 
treatment of this disease.  Rifampin and to a lesser extent erythromycin, being lipid 
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soluble, are able to penetrate caseous material (Grosset, 1980).  Hillidge administered 
erythromycin and rifampin in combination to 89 foals from one to four months of age.  
All had exhibited radiographic evidence of pulmonary abscessation suggestive of R. equi 
infection, and in 57 animals this was confirmed by culture of R. equi from tracheal 
aspirates (Hillidge, 1987).  The foals were observed daily for any adverse effects of the 
drug combination.  Thoracic radiographs were examined periodically throughout the 
course of therapy to monitor progression or resolution of disease.  When the 
radiographic appearance of the lungs returned to normal, drug therapy was discontinued.  
If the radiographs remained normal for two months, recovery from R. equi infection was 
considered complete.  Of the 89 and 57 infected foals treated, 85% and 88% recovered, 
respectively, following therapy with erythromycin and rifampin.  The duration of 
therapy in the survivors ranged from 28 to 63 days, with a mean of 44 days (Hillidge, 
1987). This study concluded that the combination of erythromycin and rifampin was 
highly effective for treating R. equi pneumonia in foals. 
 As noted in the Hillidge study, it is very important to use rifampin in 
combination with erythromycin to reduce the chance of bacteria developing resistance to 
rifampin.  Although rifampin is very potent against R. equi both in vitro and in vivo, 
bacterial resistance may develop if it is used alone to treat infections.  During that study, 
R. equi resistance to rifampin or erythromycin was not detected (Hillidge, 1987).  
However, acquired resistance among R. equi isolates has been reported after treatment 
with multiple antibiotics, including doxycycline, penicillin, erythromycin, vancomycin, 
cotrimoxazole, and rifampin (Fierer et al., 1987; Verville et al., 1994; Ferruzzi et al., 
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1997).  Considering the limited number of reported cases, varying degrees of host 
immune competence, vast geographic distribution of disease, and diverse clinical 
manifestations, it comes as no surprise that standard treatments for R. equi infection have 
not been established (Weinstock and Brown, 2002). 
 Clarithromycin is considered to be a potential alternative to erythromycin for the 
treatment of R. equi.  In a study by Jacks et al. (2002), six healthy foals were treated and 
observed after an intragastric administration of clarithromycin at a dose of 10 mg/kg 
body weight (Jacks et al., 2002).  The foals selected for this study were of different 
breeds and sex ranging from 10 to 13 weeks of age.  They were kept with their dams in 
individual stalls throughout the study.  Tablets of clarithromycin (250mg) were 
dissolved in 100ml of water and administered by nasogastric tube (Jacks et al., 2002).  
Blood samples were taken at different intervals prior to and after administration of 
clarithromycin.  Jacks et al. (2002) concluded from this study that there were no adverse 
reactions after the administration of clarithromycin.  They also stated that the half-life of 
clarithromycin was longer than reported for erythromycin, and an oral dose of 7.5 mg/kg 
given every 12 h based on MIC 90 and other properties, would appear appropriate for 
the treatment of R. equi infections in foals (Jacks et al., 2002).   
 In addition, Jacks et al. (2003) conducted a study to determine in vitro 
susceptibilities of R. equi and other common equine pathogens to azithromycin, 
clarithromycin, and twenty other antimicrobials.  Jacks examined a total of 201 bacterial 
isolates from various equine sources.  All bacterial isolates were cultured from 
tracheobronchial aspirates or postmortem specimens from pneumonic foals.  The gram-
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positive isolates studied included R. equi (n=64), beta-hemolytic streptococci 
(Streptococcus equi subspecies zooepidemicus [n=35], Streptococcus equi subspecies 
equi [n=6], Streptococcus dysgalactiae subspecies equisimilis [n=6]), Enterococcus spp. 
(n=4), and coagulase-positive Staphylococcus spp. (n=18) (Jacks et al., 2003).  Gram-
negative isolates included Salmonella enterica (n=23), Escherichia coli (n=16), 
Pasteurella spp. (n=11), Klebsiella spp. (n=10), Pseudomonas spp. (n=4), Enterobacter 
spp. (n=2), and Bordetella bronchiseptica (n=2) (Jacks et al., 2003). 
 Jacks et al. (2003) demonstrated the importance of developing an alternative 
therapy in treating R. equi by comparing the MICs of the antimicrobials for the various 
bacterial isolates.  The rational use of azithromycin and clarithromycin for the treatment 
of bacterial bronchopneumonia in foals has been precluded in part by the lack of in vitro 
susceptibility studies for equine bacterial pathogens (Jacks et al., 2003). It was shown in 
that study that clarithromycin was at least as active as erythromycin against R. equi in 
vitro, whereas azithromycin was eightfold less active (Jacks et al., 2003).   
 Although many antimicrobials are active against R. equi in vitro, they do not 
provide the same response systemically or intracellularly.  In one study, all 17 foals with 
R. equi pneumonia treated with a combination of penicillin and gentamicin died despite 
all isolates being susceptible to gentamicin and 83% being susceptible to penicillin 
(Sweeney, et al., 1987).  
  The oxazolidinones, eperezolid and linezolid, are representatives of a new class of 
orally active, synthetic antimicrobial agents that were determined to be effective in vitro 
against R. equi (Bowersock et al., 2000).  Bowersock et al. conducted a study to 
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determine the MICs of linezolid, eperezolid, premafloxacin, and several other 
antimicrobial agents against strains of R. equi isolated from humans and animals.  He 
concluded that linezolid was more active against R. equi strains than was eperezolid with 
MIC 90 of 2.0 ug/ml and 16.0 ug/ml respectively.  The study also stated that there were 
no differences in antimicrobial activity, of the agents tested, against R. equi strains from 
human and equine sources (Bowersock et al., 2000).    
 The purpose of this study was to determine the susceptibility patterns of eight 
antimicrobial agents against various strains of R. equi. Rhodococcus equi pneumonia in 
foals, and miliary tuberculosis in children caused by Mycobacterium tuberculosis, 
exhibit similar lung lesions.  Thus, the choice of these drugs is based upon their lipid 
solubility and their ability to penetrate macrophages in caseous abscess cavities of the 
lung.  The MIC values were analyzed to determine if R. equi is susceptible or resistant to 
the antimicrobial agents.  Ninety-five R. equi strains were analyzed.  MIC 50’s and 90’s 
were determined for each drug tested.  VapA-positive and VapA-negative R. equi 
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CHAPTER III 
RESEARCH DESIGN AND MATERIALS 
              The focus of this study was to determine and evaluate the MIC values of selected 
antimicrobials.    
3.1  Sources of Isolates 
 The 95 R. equi isolates were collected from the lungs and transtracheal washes of 
foals in different areas of the United States.  These isolates were maintained at the 
Equine Infectious Disease Laboratory, College of Veterinary Medicine, Texas A&M 
University. 
3.2  Quality Control Strains 
 R. equi ATCC 6939, R. equi ATCC 33701, and S. pneumoniae ATCC 49619 are 
the NCCLS (National Committee for Clinical Laboratory Standards) quality control 
strains that were used to validate susceptibility media batch to batch, to ensure proper 
handling, storage and use of strips and the correct selection of MIC end points. 
3.3  Eight Antimicrobial Agents 
  The eight antimicrobials used in this study were erythromycin, azithromycin, 
clarithromycin, rifampin, isoniazide, linezolid, ethambutol, and ethionamide.  
Erythromycin, azithromycin, and clarithromycin are classified as macrolides.  The 
macrolides inhibit protein synthesis by binding to subunits of the 50S ribosome which 
inhibits the translocation step (Prescott et al., 2000).  Rifampin is a synthetically 
modified member of the family rifamycins, isoniazide is the hydrazide of isonicotinic 
acid, ethambutol is the derivative of ethylenediamine, and ethionamide is a member of 
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the thioamides.  These four drugs are used to treat tuberculosis in humans.  Isoniazide is 
considered to be more potent than rifampin (Prescott et al., 2000).  Linezolid, a member 
of the oxazolidinones, is most active against gram-positive organisms including 
methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., 
and Streptococcus spp. (Bowersock et al., 2000).   
3.4   Antimicrobial MIC Determination 
  A procedure known as an Epsilometer test (E-test)1 was performed on each isolate 
in triplicate to determine its MIC value.  The E-test provides values that represent the 
minimum concentration (ug/ml) of a given antibiotic that inhibits the growth of a 
particular bacterium.   The E-test strips1 contain the antibiotic of choice and an MIC 
calibrated scale.  The E-test strips are 5mm wide and 60mm long, and provide data 
points that represent a continuous antimicrobial gradient with 15 concentrations.  These 
values are more precise in comparison to conventional MICs which provide 
discontinuous twofold serial dilutions (AB Biodisk, 1997).   
   Baker et al. (1991) conducted a study to show the reliability of the E-test by 
predicting the MICs and interpretative categories of susceptibility as compared with 
three conventional methods, disk diffusion, broth microdilution, and agar dilution.  On 
the basis of that study, it was concluded that comparison of the E-test to other 
conventional methods produced very good agreement of the MIC values obtained when 
testing the susceptibility of a particular bacterium.   
                                                        
1 AB Biodisk 
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 The E-test was used because its stable antibiotic gradient provided more precise 
MIC values.  Also, the E-test is superior in determining MIC values for fastidious and 
slow growing bacteria such as R. equi because of its continuous gradient.  Conventional 
methods, such as broth or agar dilution procedures are technically more difficult to 
perform, especially when testing fastidious organisms with long generation times 
(Brown and Brown, 1991).  The versatility and ease of use of the E-test make the 
method an attractive alternative to conventional dilution tests (Brown and Brown, 1991).     
  The procedure used in determining the values for each R. equi strain is as follows:  
First, a Mueller-Hinton agar2 plate supplemented with 5% sheep blood, two sterile 
swabs, inoculum suspension medium (0.85% NaCl), forceps, and colorimeter were 
obtained.  Using a sterile swab, an appropriate amount of  isolate was removed from a 
blood agar plate that had been incubated overnight.  The swab was placed into the 
inoculum suspension dispersing isolate with gentle agitation.  The swab was pulled from 
the suspension and pressed against the inner wall of the test tube to remove excess fluid.  
  The suspension was visually calibrated with a 1.0 McFarland equivalence 
turbidity standard3, confirmed and verified in a colorimeter.  After calibrating the 
suspension, the second sterile, non-toxic cotton swab was dipped into the inoculum and 
pressed against the glass to remove excess fluid.  A Mueller-Hinton blood agar plate was 
streaked in a manner that allowed even distribution of inoculum.  The plate was set aside 
                                                        
2 Remel, Inc. 
3 BBL Becton Dickinson 
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for 15 to 20 minutes to allow the excess inoculum to dry before placing the E-test strips.  
The strips were allowed to adjust at room temperature to reduce moisture.     
  Using forceps, four different E-test strips containing the antimicrobial drug of 
choice were placed onto the inoculated plate symmetrically with the MIC scale facing 
upward.  Each strip was gently pressed starting at the bottom moving upward to remove 
air bubbles to allow even distribution of the antimicrobial and ensuring stability of the 
strip.  The plate was covered and incubated at 37 C for 16 to 20 hours.  After incubation, 
the MIC values where the inhibition ellipse intersects the scale at the edge of the strip 
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CHAPTER IV 
RESULTS 
 The MIC values of the 95 R. equi strains were determined after 16 to 20 hours of 
incubation to acquire visible growth.  Each antimicrobial MIC value was analyzed and 
recorded.  The MIC values of the 3 quality control strains selected for this study were in 
the expected range. 
 The MIC values of the selected antimicrobials for R. equi are presented in the 
Appendix.  All R. equi strains in this study showed resistance to ethambutol (EB), 
ethionamide (ET) and isoniazide (IZ). Of the 95 isolates presented in this study, only 7 
were VapA-negative (non-virulent).  There was no significant difference between the 
antimicrobial susceptibility patterns of the virulent and avirulent strains of R. equi in this 
study. The MIC 50 and MIC 90 were determined by microsoft excel spreadsheet for 
each antimicrobial tested. The MIC 50 is the concentration to which 50% of the 
organisms tested are susceptible and the MIC 90 is the concentration at which 90% of 
the organisms tested are susceptible.  Detailed data on these MICs are presented in Table 
1 for all antimicrobials in this study. 
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TABLE 1. MICs of eight antimicrobial agents against 95 R. equi isolates. 
 
Antimicrobial 
 MIC (ug/ml) 
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CHAPTER V 
DISCUSSION 
 Many studies have determined in vitro susceptibilities of equine pathogens using 
disk diffusion methods, but few studies have reported MICs (Adamson et al., 1985).  In 
this study, the MICs of rifampin (RI), clarithromycin (CH), erythromycin (EM), 
linezolid (LZ), azithromycin (AZ), isoniazide (IZ), ethambutol (EB), and ethionamide 
(ET) to R. equi were determined utilizing the E-test method.  Isoniazide, ethambutol, 
ethionamide and one rifampin-resistant strain, 288, did not inhibit the growth of R. equi 
isolates with MICs > 256ug/ml.  MIC 90s for erythromycin, clarithromycin, and 
azithromycin, which are members of the macrolide group, against 95 R. equi isolates 
were 1.2 ug/ml, 0.23 ug/ml, and 2.3 ug/ml respectively.  All three were highly effective 
against R. equi, but clarithromycin demonstrated the lowest minimum inhibitory 
concentration in vitro.     
Clarithromycin is a semi-synthetic derivative of erythromycin, consisting of a 14-
membered lactone ring with substitution of a methoxy group from the C-6 hydrozyl 
group of erythromycin (Alvarez-Elcoro and Enzler, 1999). This structural difference 
gives clarithromycin several advantages over erythromycin (Jacks et al., 2002).  
Azithromycin and clarithromycin have been proposed as alternatives to erythromycin for 
the treatment of R. equi (Jacks et al., 2003), because they are more chemically stable, 
have a greater bioavailability, and achieve higher concentrations in phagocytic cells and 
tissues than erythromycin (Whitman and Tunkel, 1992).  
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 Rifampin and linezolid are both in a different class of antimicrobials.  Rifampin 
is the most important synthetically modified member of the family rifamycins (Prescott 
et al., 2000) and is combined with erythromycin in treating R. equi.  Rifampin should 
never be used alone due to the high bacterial mutation rate (Prescott et al., 2000).  
Resistance to rifampin results from the substitution of a limited number of highly 
conserved amino acids of the RNA polymerase beta subunit encoded by the rpoB gene 
(Fines et al., 2001).  Linezolid is a representative of a new class of orally active, 
synthetic antimicrobial agents, the oxazolidinones (Bowersock et al., 2000) for potential  
use in R. equi therapy.  In this study, the MIC 90s for rifampin and linezolid were 0.67 
ug/ml and 4 ug/ml, respectively, against the 95 R. equi isolates tested.  Overall, of the 
five active drugs, linezolid was least active and clarithromycin (MIC 90 = 0.23 ug/ml) 
















This study revealed that although clarithromycin was shown to be the most active 
against R. equi in vitro, more research is needed in vivo before initiating treatment with 
clarithromycin in infected foals. This study also indicated that rifampin (MIC 90 = 
0.67ug/ml) was more active than erythromycin (MIC 90 = 1.2 ug/ml) against at least 
90% of the R. equi isolates in vitro. Both are still highly active against R. equi and 
should continue to be the primary drug therapy for treating this infection until further 
studies have been performed on the MICs and oral disposition of clarithromycin, 
azithromycin, linezolid and other antimicrobials.  The rifampin-resistant strain shown in 
this study, validates the reasoning for investigating new antimicrobial agents for 
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APPENDIX 
 
Data for the eight antimicrobial agents against 95 R. equi isolates. 
 
Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
          
6939  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
          
          
          
33701  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
          
          
          
49619  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
99-244 0.500 >256 0.125 0.750 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  1.000 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.667 >256 0.168 0.917 >256 >256 4.000 2.000
          
          
99-243 0.190 >256 0.094 0.500 >256 >256 4.000 2.000
  0.380 >256 0.125 0.750 >256 >256 3.000 2.000
  0.500 >256 0.094 0.750 >256 >256 3.000 1.500
          
Average MIC 0.357 >256 0.104 0.667 >256 >256 3.333 1.833
          
          
99-240 0.047 >256 0.125 0.750 >256 >256 3.000 2.000
  0.047 >256 0.190 0.750 >256 >256 4.000 2.000
  0.047 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.047 >256 0.168 0.833 >256 >256 3.333 2.000
          
          
99-239 0.750 >256 0.190 0.750 >256 >256 4.000 2.000
  0.500 >256 0.125 0.750 >256 >256 3.000 2.000
  0.500 >256 0.190 0.750 >256 >256 3.000 1.500
Average MIC 0.583 >256 0.168 0.168 >256 >256 3.333 1.833
         
99-237 0.500 >256 0.125 0.750 >256 >256 4.000 1.500
  0.750 >256 0.125 0.750 >256 >256 3.000 1.500
  0.380 >256 0.125 1.000 >256 >256 4.000 1.500
          
Average MIC 0.543 >256 0.125 0.833 >256 >256 3.667 1.500
          
          
99-236 0.500 >256 0.190 0.750 >256 >256 4.000 1.500
  0.750 >256 0.125 0.750 >256 >256 4.000 2.000
  0.500 >256 0.125 0.750 >256 >256 4.000 2.000
          
Average MIC 0.583 >256 0.147 0.750 >256 >256 4.000 1.833
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
          
6939  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
          
          
          
33701  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
          
          
          
49619  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
  0 0 0 0 0 0 0 0 
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
98-89  0.380 >256 0.250 0.750 >256 >256 4.000 2.000
  0.500 >256 0.250 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.420 >256 0.230 0.917 >256 >256 3.667 2.000
          
          
98-90  0.750 >256 0.190 1.000 >256 >256 4.000 2.000
  1.000 >256 0.190 1.000 >256 >256 4.000 2.000
  1.000 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.917 >256 0.190 1.000 >256 >256 4.000 2.000
          
          
98-92  0.500 >256 0.250 1.500 >256 >256 6.000 2.000
  0.500 >256 0.250 1.000 >256 >256 4.000 2.000
  0.500 >256 0.250 1.000 >256 >256 4.000 2.000
          
Average MIC 0.500 >256 0.250 1.167 >256 >256 4.667 2.000
          
          
98-93  0.500 >256 0.250 1.000 >256 >256 4.000 2.000
  1.000 >256 0.250 1.000 >256 >256 6.000 2.000
  0.500 >256 0.250 1.000 >256 >256 4.000 2.000
          
Average MIC 0.667 >256 0.250 1.000 >256 >256 4.667 2.000
          
          
98-94  0.500 >256 0.190 0.750 >256 >256 4.000 2.000
  0.750 >256 0.250 1.000 >256 >256 4.000 2.000
  0.500 >256 0.250 1.000 >256 >256 4.000 1.500
          
Average MIC 0.583 >256 0.230 0.917 >256 >256 4.000 1.833
          
          
98-95  0.380 >256 0.125 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.125 1.000 >256 >256 4.000 2.000
          
Average MIC 0.460 >256 0.147 1.000 >256 >256 4.000 2.000
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
          
6939  0.380 >256 0.125 0.750 >256 >256 3.000 1.500
  0.250 >256 0.125 0.750 >256 >256 3.000 1.500
  0.380 >256 0.125 0.750 >256 >256 3.000 1.500
          
Average MIC 0.337 >256 0.125 0.750 >256 >256 3.000 1.500
          
          
33701  0.380 >256 0.125 0.500 >256 >256 4.000 2.000
  0.380 >256 0.125 0.500 >256 >256 4.000 1.500
  0.380 >256 0.125 0.750 >256 >256 4.000 2.000
          
Average MIC 0.380 >256 0.125 0.583 >256 >256 4.000 1.833
          
          
49619  0.125 >256 0.047 0.094 >256 >256 2.000 0.190
  0.125 >256 0.047 0.125 >256 >256 2.000 0.125
  0.125 >256 0.032 0.094 >256 >256 1.500 0.190
          
Average MIC 0.125 >256 0.042 0.104 >256 >256 1.833 0.168
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
98-87  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.667 2.000
          
          
98-88  1.000 >256 0.190 1.500 >256 >256 3.000 2.000
  1.000 >256 0.380 1.500 >256 >256 3.000 3.000
  0.380 >256 0.380 1.000 >256 >256 4.000 3.000
          
Average MIC 0.793 >256 0.317 1.333 >256 >256 3.333 2.667
          
          
98-96  0.380 >256 0.190 1.500 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.380 >256 0.190 1.167 >256 >256 4.000 2.000
          
          
98-97  0.380 >256 0.190 1.000 >256 >256 3.000 1.500
  0.380 >256 0.190 1.000 >256 >256 4.000 1.500
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.667 1.667
          
          
98-99  0.380 >256 0.190 1.500 >256 >256 4.000 2.000
  0.380 >256 0.380 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.500 >256 >256 3.000 1.500
          
Average MIC 0.380 >256 0.253 1.333 >256 >256 3.667 1.833
          
          
98-100 0.500 >256 0.190 0.750 >256 >256 4.000 1.500
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
         
Average MIC 0.460 >256 0.190 0.917 >256 >256 4.000 1.833
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Antibiotics RI EB CH EM IZ ET LZ AZ 
Controls         
          
6939  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
         
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.333 2.000
          
33701  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.460 >256 0.190 1.000 >256 >256 4.000 2.000
          
          
49619  0.125 >256 0.064 0.094 >256 >256 3.000 0.250
  0.125 >256 0.064 0.094 >256 >256 4.000 0.250
  0.125 >256 0.064 0.094 >256 >256 3.000 0.250
          
Average MIC 0.125 >256 0.064 0.094 >256 >256 3.333 0.250
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
98-78  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 6.000 2.000
  0.500 >256 0.190 0.750 >256 >256 4.000 3.000
          
Average MIC 0.500 >256 0.190 0.917 >256 >256 4.667 2.333
          
          
98-79  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.420 >256 0.190 1.000 >256 >256 3.333 2.000
          
98-80  0.500 >256 0.190 1.500 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.500 >256 >256 4.000 2.000
          
Average MIC 0.460 >256 0.190 1.333 >256 >256 4.000 2.000
          
98-81  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.250 1.500 >256 >256 4.000 3.000
          
Average MIC 0.420 >256 0.210 1.167 >256 >256 4.000 2.333
          
98-84  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
98-85  1.000 >256 0.190 1.000 >256 >256 4.000 3.000
  0.750 >256 0.190 1.000 >256 >256 3.000 2.000
  0.750 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.833 >256 0.190 1.000 >256 >256 3.667 2.333
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
          
6939  0.190 >256 0.125 0.750 >256 >256 3.000 2.000
  0.190 >256 0.125 0.750 >256 >256 2.000 2.000
  0.380 >256 0.125 0.750 >256 >256 4.000 2.000
          
Average MIC 0.253 >256 0.125 0.750 >256 >256 3.000 2.000
          
          
33701  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.460 >256 0.190 1.000 >256 >256 4.000 2.000
          
          
49619  0.125 >256 0.064 0.094 >256 >256 4.000 0.250
  0.125 >256 0.064 0.094 >256 >256 4.000 0.250
  0.125 >256 0.064 0.094 >256 >256 3.000 0.250
          
Average MIC 0.125 >256 0.064 0.094 >256 >256 3.667 0.250
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
98-69  0.750 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.583 >256 0.190 1.000 >256 >256 3.000 2.000
          
          
98-71  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 3.000
  0.500 >256 0.190 0.750 >256 >256 3.000 2.000
          
Average MIC 0.500 >256 0.190 0.917 >256 >256 3.000 2.333
          
          
98-72  0.230 >256 0.190 1.000 >256 >256 3.000 2.000
  0.230 >256 0.250 1.000 >256 >256 3.000 2.000
  0.032 >256 0.190 0.750 >256 >256 2.000 2.000
          
Average MIC 0.164 >256 0.210 0.917 >256 >256 2.667 2.000
          
          
98-73  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 3.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
         
Average MIC 0.500 >256 0.190 1.000 >256 >256 4.000 2.333
          
98-75  0.190 >256 0.190 1.000 >256 >256 4.000 2.000
  0.250 >256 0.190 1.000 >256 >256 4.000 2.000
  0.190 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.210 >256 0.190 1.000 >256 >256 4.000 2.000
          
          
98-77  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.420 >256 0.190 1.000 >256 >256 3.667 2.000
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
          
6939  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.125 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.168 1.000 >256 >256 3.000 2.000
          
          
33701  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.125 1.000 >256 >256 4.000 2.000
  0.500 >256 0.125 1.000 >256 >256 4.000 2.000
          
Average MIC 0.460 >256 0.147 1.000 >256 >256 4.000 2.000
          
          
49619  0.064 >256 0.032 1.000 >256 >256 1.500 0.094
  0.094 >256 0.032 1.000 >256 >256 2.000 0.125
  0.094 >256 0.047 1.000 >256 >256 2.000 0.125
          
Average MIC 0.084 >256 0.037 1.000 >256 >256 1.833 0.115
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
98-61  0.750 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.750 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.667 >256 0.190 1.000 >256 >256 3.000 2.000
          
          
98-63  0.750 >256 0.190 1.000 >256 >256 3.000 2.000
  0.750 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
         
Average MIC 0.667 >256 0.190 1.000 >256 >256 3.333 2.000
          
98-64  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
98-65  0.023 >256 0.250 1.000 >256 >256 2.000 2.000
  0.023 >256 0.250 0.750 >256 >256 3.000 3.000
  0.023 >256 0.250 1.000 >256 >256 3.000 2.000
          
Average MIC 0.023 >256 0.250 0.917 >256 >256 2.667 2.333
          
98-66  0.500 >256 0.190 1.500 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.460 >256 0.190 1.167 >256 >256 3.333 2.000
          
98-68  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 0.750 >256 >256 4.000 2.000
          
Average MIC 0.460 >256 0.190 0.917 >256 >256 4.000 2.000
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
          
6939  0.380 >256 0.190 0.750 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.460 >256 0.190 0.917 >256 >256 3.000 2.000
          
33701  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.420 >256 0.190 1.000 >256 >256 4.000 2.000
          
49619  0.125 >256 0.064 0.094 >256 >256 3.000 0.190
  0.125 >256 0.047 0.094 >256 >256 2.000 0.125
  0.125 >256 0.064 0.094 >256 >256 2.000 0.190
          
Average MIC 0.125 >256 0.058 0.094 >256 >256 2.333 0.168
          
             37 
 
Antibiotics RI EB CH EM IZ ET LZ AZ 
R. Equi. Strains       
97-42  0.750 >256 0.190 0.750 >256 >256 3.000 2.000
  0.750 >256 0.190 1.000 >256 >256 4.000 2.000
  0.750 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.750 >256 0.190 0.917 >256 >256 3.667 2.000
          
97-43  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.250 1.000 >256 >256 3.000 3.000
  0.380 >256 0.190 1.000 >256 >256 4.000 3.000
          
Average MIC 0.460 >256 0.210 1.000 >256 >256 3.333 2.667
          
97-44  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 0.750 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 0.917 >256 >256 3.000 2.000
          
97-45  0.500 >256 0.190 1.500 >256 >256 4.000 2.000
  0.500 >256 0.190 1.500 >256 >256 4.000 2.000
  0.500 >256 0.190 1.500 >256 >256 4.000 2.000
          
Average MIC 0.500 >256 0.190 1.500 >256 >256 4.000 2.000
          
98-56  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.500 >256 0.190 1.000 >256 >256 3.667 2.000
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
6939  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 3.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.000 2.333
          
33701  0.500 >256 0.190 0.750 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.500 >256 0.190 0.917 >256 >256 3.667 2.000
          
49619  0.094 >256 0.047 0.064 >256 >256 2.000 0.190
  0.064 >256 0.047 0.047 >256 >256 2.000 0.190
  0.064 >256 0.047 0.064 >256 >256 1.500 0.190
          
Average MIC 0.074 >256 0.047 0.058 >256 >256 1.833 0.190
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Antibiotics RI EB CH EM IZ ET LZ AZ 
R. Equi. Strains       
          
97-37  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.420 >256 0.190 1.000 >256 >256 3.000 2.000
          
97-38  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.250 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.337 >256 0.190 1.000 >256 >256 3.000 2.000
          
          
97-39  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 3.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.333 2.333
          
          
97-40  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.667 2.000
          
          
97-41  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.500 >256 0.190 1.000 >256 >256 3.667 2.000
          
          
98-53  0.380 >256 0.190 0.750 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 0.917 >256 >256 3.667 2.000
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
          
6939  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.333 2.000
          
          
33701  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.420 >256 0.190 1.000 >256 >256 3.333 2.000
          
          
49619  0.094 >256 0.047 0.064 >256 >256 2.000 0.190
  0.094 >256 0.047 0.064 >256 >256 2.000 0.190
  0.094 >256 0.047 0.064 >256 >256 2.000 0.190
          
Average MIC 0.094 >256 0.047 0.064 >256 >256 2.000 0.190
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
97-48  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.250 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.210 1.000 >256 >256 3.000 2.000
          
97-47  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.460 >256 0.190 1.000 >256 >256 3.000 2.000
          
98-52  0.500 >256 0.250 1.000 >256 >256 3.000 2.000
  0.380 >256 0.250 1.000 >256 >256 3.000 2.000
  0.380 >256 0.250 1.500 >256 >256 3.000 2.000
          
Average MIC 0.420   >256 0.250 1.167 >256 >256 3.000 2.000
          
98-55  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.420 >256 0.190 1.000 >256 >256 3.000 2.000
          
98-57  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.460 >256 0.190 1.000 >256 >256 3.667 2.000
          
98-58  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 3.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.420 >256 0.190 1.000 >256 >256 3.000 2.333
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Antibiotics RI EB CH EM IZ ET LZ AZ 
Controls         
          
6939  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.460 >256 0.190 1.000 >256 >256 3.000 2.000
          
33701  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.125 1.000 >256 >256 3.000 2.000
          
Average MIC 0.420 >256 0.168 1.000 >256 >256 3.333 2.000
49619  0.064 >256 0.047 0.064 >256 >256 2.000 0.250
  0.094 >256 0.047 0.064 >256 >256 1.500 0.250
  0.094 >256 0.064 0.064 >256 >256 2.000 0.250
          
Average MIC 0.084 >256 0.053 0.064 >256 >256 1.833 0.250
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
71  0.032 >256 0.250 1.000 >256 >256 3.000 2.000
  0.032 >256 0.250 1.000 >256 >256 3.000 2.000
  0.032 >256 0.190 1.000 >256 >256 3.000 3.000
          
Average MIC 0.032 >256 0.230 1.000 >256 >256 3.000 2.333
          
          
72  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.250 1.000 >256 >256 3.000 2.000
  0.380 >256 0.250 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.230 1.000 >256 >256 3.000 2.000
          
97-35  0.250 >256 0.190 1.000 >256 >256 4.000 2.000
  0.190 >256 0.190 1.000 >256 >256 4.000 2.000
  0.190 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.210 >256 0.190 1.000 >256 >256 3.667 2.000
          
          
97-36  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.250 1.000 >256 >256 3.000 2.000
          
Average MIC 0.500 >256 0.210 1.000 >256 >256 3.333 2.000
          
98-60  0.500 >256 0.250 1.000 >256 >256 3.000 2.000
  0.500 >256 0.250 1.000 >256 >256 3.000 3.000
  0.500 >256 0.250 1.000 >256 >256 3.000 2.000
          
Average MIC 0.500 >256 0.250 1.000 >256 >256 3.000 2.333
          
          
98-59  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.420 >256 0.190 1.000 >256 >256 3.000 2.000
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
          
Controls         
          
6939  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
33701  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.460 >256 0.190 1.000 >256 >256 3.667 2.000
          
49619  0.064 >256 0.047 0.064 >256 >256 1.500 0.094
  0.064 >256 0.047 0.064 >256 >256 1.500 0.125
  0.047 >256 0.047 0.064 >256 >256 1.500 0.125
          
Average MIC 0.058 >256 0.047 0.064 >256 >256 1.500 0.115
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
7  0.023 >256 0.190 1.000 >256 >256 3.000 2.000
  0.023 >256 0.190 1.000 >256 >256 3.000 2.000
  0.023 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.023 >256 0.190 1.000 >256 >256 3.000 2.000
          
          
14  0.380 >256 0.250 1.000 >256 >256 3.000 2.000
  0.380 >256 0.250 1.000 >256 >256 3.000 2.000
  0.500 >256 0.250 1.500 >256 >256 3.000 3.000
          
Average MIC 0.420 >256 0.250 1.167 >256 >256 3.000 2.333
          
          
73  0.023 >256 0.190 1.000 >256 >256 4.000 2.000
  0.023 >256 0.190 1.000 >256 >256 3.000 2.000
  0.023 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.023 >256 0.190 1.000 >256 >256 3.333 2.000
          
          
97-36  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.250 1.000 >256 >256 3.000 2.000
  0.500 >256 0.250 1.000 >256 >256 3.000 2.000
          
Average MIC 0.500 >256 0.230 1.000 >256 >256 3.000 2.000
         
99-242 0.380 >256 0.250 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.250 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.377 >256 0.210 1.000 >256 >256 3.000 2.000
          
          
97-35  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.250 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.337 >256 0.190 1.000 >256 >256 3.000 2.000
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
          
6939  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.420 >256 0.190 1.000 >256 >256 3.333 2.000
          
          
33701  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 1.500
          
Average MIC 0.460 >256 0.190 1.000 >256 >256 4.000 1.833
          
          
49619  0.064 >256 0.032 0.047 >256 >256 1.000 0.094
  0.064 >256 0.032 0.047 >256 >256 1.500 0.125
  0.064 >256 0.047 0.064 >256 >256 1.500 0.125
          
Average MIC 0.064 >256 0.037 0.053 >256 >256 1.333 0.115
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
65  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 2.000 1.500
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.500 >256 0.190 1.000 >256 >256 2.667 1.833
          
66  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.420 >256 0.190 1.000 >256 >256 3.000 2.000
          
68  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.667 2.000
          
          
69  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
          
70  0.750 >256 0.190 1.000 >256 >256 3.000 2.000
  0.750 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.667 >256 0.190 1.000 >256 >256 3.333 2.000
          
          
19757-4 0.380 >256 0.250 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.250 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.230 1.000 >256 >256 3.000 2.000
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
          










































          














          
33701  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.667 2.000
          
49619  0.094 >256 0.047 0.064 >256 >256 2.000 0.094
  0.094 >256 0.047 0.047 >256 >256 1.500 0.094
  0.064 >256 0.032 0.064 >256 >256 2.000 0.125
          
Average MIC 0.084 >256 0.042 0.058 >256 >256 1.833 0.104
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
28  0.750 >256 0.190 1.000 >256 >256 3.000 2.000
  0.750 >256 0.250 1.000 >256 >256 3.000 2.000
  0.750 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.750 >256 0.210 1.000 >256 >256 3.333 2.000
          
          
29  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.250 >256 0.190 1.000 >256 >256 3.000 2.000
  0.250 >256 0.125 1.000 >256 >256 4.000 2.000
          
Average MIC 0.293 >256 0.168 1.000 >256 >256 3.667 2.000
          
          
30  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.460 >256 0.190 1.000 >256 >256 3.000 2.000
          
          
59  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.250 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.210 1.000 >256 >256 3.667 2.000
          
          
61  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.420 >256 0.190 1.000 >256 >256 4.000 2.000
          
          
62  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.667 2.000
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Antibiotics RI EB CH EM IZ ET LZ AZ 
Controls         
          
6939  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
33701  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
          
49619  0.064 >256 0.047 0.064 >256 >256 3.000 0.190
  0.064 >256 0.047 0.064 >256 >256 2.000 0.190
  0.094 >256 0.047 0.064 >256 >256 2.000 0.190
          
Average MIC 0.074 >256 0.047 0.064 >256 >256 2.333 0.190
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
20A  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.125 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.420 >256 0.168 1.000 >256 >256 3.000 2.000
          
          
20  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.125 1.000 >256 >256 4.000 2.000
          
Average MIC 0.500 >256 0.168 1.000 >256 >256 3.333 2.000
          
          
23  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.500 >256 >256 4.000 2.000
          
Average MIC 0.380 >256 0.190 1.167 >256 >256 3.667 2.000
          
          
24  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.125 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.500 >256 0.168 1.000 >256 >256 4.000 2.000
          
          
25  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.667 2.000
          
          
27  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.460 >256 0.190 1.000 >256 >256 3.667 2.000
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
          
6939  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.500 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 1.167 >256 >256 3.000 2.000
          
          
33701  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
          
Average MIC 0.460 >256 0.190 1.000 >256 >256 3.667 2.000
          
49619  0.064 >256 0.032 0.047 >256 >256 2.000 0.125
  0.047 >256 0.032 0.047 >256 >256 2.000 0.125
  0.047 >256 0.032 0.047 >256 >256 2.000 0.125
          
Average MIC 0.053 >256 0.032 0.047 >256 >256 2.000 0.125
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
6  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.500 >256 0.190 1.000 >256 >256 3.333 2.000
          
9  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.667 2.000
          
          
16  0.380 >256 0.190 1.000 >256 >256 3.000 1.500
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 0.750 >256 >256 3.000 1.500
          
Average MIC 0.380 >256 0.190 0.917 >256 >256 3.000 1.667
          
          
17  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.667 2.000
          
          
18  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
          
19  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.000 2.000
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
Controls         
          
6939  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.380 >256 0.190 1.000 >256 >256 3.333 2.000
          
          










































          














          
49619  0.0940 >256 0.0320 0.0320 >256 >256 2.000 0.0940
  0.0640 >256 0.0470 0.0470 >256 >256 1.500 0.0940
  0.0640 >256 0.0230 0.0470 >256 >256 1.500 0.0940
          
Average MIC 0.0740 >256 0.0340 0.0420 >256 >256 1.666 0.0940
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Antibiotics RI EB CH EM IZ ET LZ AZ 
          
R. Equi. Strains       
          
98-101 0.380 >256 0.125 1.000 >256 >256 3.000 2.000
  0.380 >256 0.125 1.000 >256 >256 3.000 2.000
  0.380 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC 0.380 >256 0.147 1.000 >256 >256 3.000 2.000
          
          
99-108 0.094 >256 0.064 0.500 >256 >256 3.000 2.000
  0.094 >256 0.094 0.750 >256 >256 3.000 2.000
  0.094 >256 0.125 0.500 >256 >256 3.000 2.000
          
Average MIC 0.094 >256 0.094 0.583 >256 >256 3.000 2.000
          
          
99-109 0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.125 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 4.000 2.000
          
Average MIC 0.460 >256 0.168 1.000 >256 >256 3.333 2.000
          
          
99-110 0.380 >256 0.064 0.190 >256 >256 2.000 0.500
  0.380 >256 0.064 0.190 >256 >256 2.000 0.750
  0.500 >256 0.064 0.250 >256 >256 2.000 0.750
          
Average MIC 0.420 >256 0.064 0.210 >256 >256 2.000 0.667
          
          
99-112 0.380 >256 0.190 1.000 >256 >256 3.000 2.000
  0.500 >256 0.190 1.000 >256 >256 3.000 2.000
  0.380 >256 0.125 0.500 >256 >256 4.000 2.000
          
Average MIC 0.420 >256 0.168 0.833 >256 >256 3.333 2.000
          
          
288  >256 >256 0.190 1.000 >256 >256 3.000 2.000
  >256 >256 0.190 1.000 >256 >256 3.000 2.000
  >256 >256 0.190 1.000 >256 >256 3.000 2.000
          
Average MIC >256 >256 0.190 1.000 >256 >256 3.000 2.000
 
RI (rifampin)  EB (ethambutol)  CH (clarithromycin)  EM (erythromycin)   
 
IZ (isoniazide)  ET (ethionamide)  LZ (linezolid)  AZ (azithromycin)
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